These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 36758444)

  • 21. Decreased expression of synaptic vesicle protein 2A, the binding site for levetiracetam, during epileptogenesis and chronic epilepsy.
    van Vliet EA; Aronica E; Redeker S; Boer K; Gorter JA
    Epilepsia; 2009 Mar; 50(3):422-33. PubMed ID: 18717715
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The human synaptic vesicle protein, SV2A, functions as a galactose transporter in Saccharomyces cerevisiae.
    Madeo M; Kovács AD; Pearce DA
    J Biol Chem; 2014 Nov; 289(48):33066-71. PubMed ID: 25326386
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biallelic variants in the synaptic vesicle glycoprotein 2 A are associated with epileptic encephalopathy.
    Al-Maawali A; Al-Murshedi F; Al-Futaisi A; Mansy A; Al-Habsi A; Girisha KM
    Eur J Hum Genet; 2024 Feb; 32(2):243-246. PubMed ID: 37985816
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential expression of synaptic vesicle protein 2A after status epilepticus and during epilepsy in a lithium-pilocarpine model.
    Contreras-García IJ; Pichardo-Macías LA; Santana-Gómez CE; Sánchez-Huerta K; Ramírez-Hernández R; Gómez-González B; Rocha L; Mendoza Torreblanca JG
    Epilepsy Behav; 2018 Nov; 88():283-294. PubMed ID: 30336420
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy.
    Kaminski RM; Matagne A; Leclercq K; Gillard M; Michel P; Kenda B; Talaga P; Klitgaard H
    Neuropharmacology; 2008 Mar; 54(4):715-20. PubMed ID: 18207204
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Further evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein.
    Wood MD; Sands ZA; Vandenplas C; Gillard M
    Epilepsia; 2018 Sep; 59(9):e147-e151. PubMed ID: 30144048
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Integration of postmortem amygdala expression profiling, GWAS, and functional cell culture assays: neuroticism-associated synaptic vesicle glycoprotein 2A (SV2A) gene is regulated by miR-133a and miR-218.
    Jurkiewicz M; Moser D; Koller A; Yu L; Chen EI; Bennett DA; Canli T
    Transl Psychiatry; 2020 Aug; 10(1):297. PubMed ID: 32839459
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment.
    Klitgaard H; Matagne A; Nicolas JM; Gillard M; Lamberty Y; De Ryck M; Kaminski RM; Leclercq K; Niespodziany I; Wolff C; Wood M; Hannestad J; Kervyn S; Kenda B
    Epilepsia; 2016 Apr; 57(4):538-48. PubMed ID: 26920914
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of synaptic vesicle protein 2A in epilepsy-associated brain tumors and in the peritumoral cortex.
    de Groot M; Toering ST; Boer K; Spliet WG; Heimans JJ; Aronica E; Reijneveld JC
    Neuro Oncol; 2010 Mar; 12(3):265-73. PubMed ID: 20167814
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Mitochondrial Role of SV2a Protein in Aging and Alzheimer's Disease: Studies with Levetiracetam.
    Stockburger C; Miano D; Baeumlisberger M; Pallas T; Arrey TN; Karas M; Friedland K; Müller WE
    J Alzheimers Dis; 2016; 50(1):201-15. PubMed ID: 26639968
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic variation at the synaptic vesicle gene SV2A is associated with schizophrenia.
    Mattheisen M; Mühleisen TW; Strohmaier J; Treutlein J; Nenadic I; Alblas M; Meier S; Degenhardt F; Herms S; Hoffmann P; Witt SH; Giegling I; Sauer H; Schulze TG; Rujescu D; Nöthen MM; Rietschel M; Cichon S
    Schizophr Res; 2012 Nov; 141(2-3):262-5. PubMed ID: 23017826
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein.
    Wood MD; Gillard M
    Epilepsia; 2017 Feb; 58(2):255-262. PubMed ID: 28012162
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Levetiracetam treatment ameliorates LRRK2 pathological mutant phenotype.
    Rassu M; Biosa A; Galioto M; Fais M; Sini P; Greggio E; Piccoli G; Crosio C; Iaccarino C
    J Cell Mol Med; 2019 Dec; 23(12):8505-8510. PubMed ID: 31560168
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties.
    Gillard M; Fuks B; Leclercq K; Matagne A
    Eur J Pharmacol; 2011 Aug; 664(1-3):36-44. PubMed ID: 21575627
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A.
    Matagne A; Margineanu DG; Kenda B; Michel P; Klitgaard H
    Br J Pharmacol; 2008 Aug; 154(8):1662-71. PubMed ID: 18500360
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combining modelling and mutagenesis studies of synaptic vesicle protein 2A to identify a series of residues involved in racetam binding.
    Shi J; Anderson D; Lynch BA; Castaigne JG; Foerch P; Lebon F
    Biochem Soc Trans; 2011 Oct; 39(5):1341-7. PubMed ID: 21936812
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synaptic vesicle glycoprotein 2A (SV2A) regulates kindling epileptogenesis via GABAergic neurotransmission.
    Tokudome K; Okumura T; Shimizu S; Mashimo T; Takizawa A; Serikawa T; Terada R; Ishihara S; Kunisawa N; Sasa M; Ohno Y
    Sci Rep; 2016 Jun; 6():27420. PubMed ID: 27265781
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Levetiracetam reverses synaptic deficits produced by overexpression of SV2A.
    Nowack A; Malarkey EB; Yao J; Bleckert A; Hill J; Bajjalieh SM
    PLoS One; 2011; 6(12):e29560. PubMed ID: 22220214
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Temporal and spatial changes in synaptic vesicle glycoprotein 2A (SV2A) under kainic acid induced epileptogenesis: An autoradiographic study.
    Pazarlar BA; Madsen CA; Oyar EÖ; Eğilmez CB; Mikkelsen JD
    Epilepsy Res; 2022 Jul; 183():106926. PubMed ID: 35526328
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluating the In Vivo Specificity of [
    Serrano ME; Becker G; Bahri MA; Seret A; Mestdagh N; Mercier J; Mievis F; Giacomelli F; Lemaire C; Salmon E; Luxen A; Plenevaux A
    Molecules; 2019 May; 24(9):. PubMed ID: 31052478
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.